Anti-nerve growth factor antibodies may relieve osteoarthritis pain and improve function

Anti-nerve growth factor antibodies, anti-NGF antibodies, tanuzemab, fasinumab, arthritis drug, arthritis pain, arthritis digestBlocking nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). Studies have looked at if anti-NGF antibodies can work on osteoarthritis pain and chronic low-back pain, and a group of researchers decided to analyse them to see what trends emerged, reporting their findings in Current Rheumatology Reports.

The work shows anti-NGF antibodies did reduce pain scores and increase physical function. The two drugs in development, tanuzemab and fasinumab, are performing well in trials but are not yet available to patients.

The research group concludes that: “anti-NGF antibodies can relieve pain and improve function in patients with osteoarthritis pain and chronic low-back pain.”

Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2019.

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.